InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.investorsoup.com/lp/SOMX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The Company's product Silenor® (doxepin) has been approved by the FDA for the treatment of insomnia characterized by difficulty with sleep maintenance.

Message Board Search for SOMX: http://www.boardcentral.com/boards/SOMX

In the report, the analyst notes:

"SOMX recently announced the FDA has approved the New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance. SOMX shares more than doubled on the news.

"As a result of the NDA approval for Silenor, SOMX will be required to make a $1.0 million milestone payment to its licensor for Silenor pursuant to its existing license agreement. SOMX had $5.2 million in cash, cash equivalents and marketable securities as of December 31 and said it has sufficient funds to operate through the second quarter of 2010."